News | May 26, 2025
Gland Pharma Q4 FY25 PAT falls to Rs. 186.5 Cr
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
